Kristopher D. Brown Kristopher D. Brown

Mr. Brown has advised on award-winning life sciences deals, including:

Capital Markets

• Olink Holding AB (publ) in its $265 million IPO on Nasdaq in the U.S.
• Calliditas Therapeutics in its upsized $90 million IPO on Nasdaq in the U.S.
• Bicycle Therapeutics in its $60 million IPO on Nasdaq in the U.S.
• Advaxis, Inc. in multiple follow-on financings on Nasdaq
• Zealand Pharma in its $75 million IPO on Nasdaq in the U.S.*
• Forward Pharma in its $221 million IPO on Nasdaq in the U.S., which won M&A Advisor’s “Healthcare/Life Sciences Sector Deal of the Year” award*

M+A

• Johnson & Johnson in the sale of its BabyCenter business to Everyday Health Group
• Johnson & Johnson in the sale of one of its drug product lines to Baxter
• Johnson & Johnson in the transfer of collaboration rights and assets to Pharma Mar
• Remedy Pharmaceuticals’ sale to Biogen, in a transaction which received a “Commended” ranking at the Financial Times North American Innovative Lawyers 2017 Awards*
• Lazada Group on the $1 billion sale of a controlling stake in the company to Alibaba, which was named “M&A Deal of the Year: Southeast Asia” at The Asian Lawyer’s 2017 Asia Legal Awards*
• AM-Pharma’s sale of a minority interest in the company to Pfizer Inc. and related option payment, which was a finalist for the 2015 Scrip Awards*

Licensing + Collaborations

• Johnson & Johnson in its strategic alliance with Apple to deploy the Apple Watch to detect atrial fibrillation
• Johnson & Johnson in its partnership with Verily (f/k/a Google Life Sciences) to innovate advanced surgical robots, which won LMG’s “2015 Collaboration Deal of the Year”*

Royalty Monetizations

• Barings in the purchase of certain rights from George Washington University related to the license by GWU of its vasoconstrictor drug to La Jolla Pharmaceutical Company
• Onxeo in the $7.5 million royalty and milestone monetization from SWK Holdings of Onxeo’s oncology drug to treat refractory peripheral T cell lymphoma
• Zealand Pharma in the $205 million royalty and milestone monetization from Royalty Pharma of Zealand’s GLP-1 diabetes franchise
• Zealand Pharma’s monetization of certain royalty rights under its license agreement with Sanofi-Aventis, which was a finalist for the 2015 Scrip Awards*

Venture Capital

• Johnson and Johnson UK Treasury Company Limited as lead investor of the $1.3 billion Series B financing of Grail, Inc., which was named LMG Life Sciences 2017 “Impact Deal of the Year”*

*Denotes experience prior to joining Goodwin.